McGuire Investment Group LLC Sells 6,521 Shares of IQVIA Holdings Inc. (NYSE:IQV)

McGuire Investment Group LLC decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 11.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,892 shares of the medical research company's stock after selling 6,521 shares during the period. McGuire Investment Group LLC's holdings in IQVIA were worth $9,325,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Marathon Asset Management Ltd raised its stake in shares of IQVIA by 14.4% in the 1st quarter. Marathon Asset Management Ltd now owns 171,407 shares of the medical research company's stock worth $30,218,000 after buying an additional 21,614 shares in the last quarter. Highland Capital Management LLC grew its holdings in IQVIA by 2.3% during the first quarter. Highland Capital Management LLC now owns 6,541 shares of the medical research company's stock worth $1,153,000 after acquiring an additional 148 shares during the period. BSW Wealth Partners raised its position in IQVIA by 34.3% in the first quarter. BSW Wealth Partners now owns 1,540 shares of the medical research company's stock worth $272,000 after acquiring an additional 393 shares in the last quarter. Golden State Wealth Management LLC lifted its holdings in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after acquiring an additional 130 shares during the last quarter. Finally, Strategic Investment Advisors MI bought a new position in shares of IQVIA during the 1st quarter valued at about $377,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 0.1%

Shares of NYSE IQV traded up $0.22 during mid-day trading on Monday, reaching $157.69. The company had a trading volume of 2,920,637 shares, compared to its average volume of 1,649,313. The company has a debt-to-equity ratio of 2.19, a quick ratio of 0.82 and a current ratio of 0.82. IQVIA Holdings Inc. has a twelve month low of $100.00 and a twelve month high of $252.88. The stock's 50 day moving average is $149.26 and its 200-day moving average is $174.17. The stock has a market capitalization of $27.28 billion, a PE ratio of 21.48, a price-to-earnings-growth ratio of 1.75 and a beta of 1.28.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The business's quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.54 earnings per share. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the subject of several recent research reports. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Robert W. Baird cut their price objective on IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. HSBC lowered IQVIA from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. UBS Group cut their target price on IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Redburn Partners set a $188.00 price target on IQVIA in a research report on Friday, May 23rd. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.